Brokerages Set MindWalk Holdings Corp. (NASDAQ:HYFT) PT at $5.00

MindWalk Holdings Corp. (NASDAQ:HYFT) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $5.00.

Several analysts recently weighed in on HYFT shares. JonesTrading initiated coverage on MindWalk in a research report on Thursday, April 16th. They set a “buy” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, Wall Street Zen cut shares of MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th.

Institutional Investors Weigh In On MindWalk

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in MindWalk in the 4th quarter worth about $51,000. XTX Topco Ltd grew its holdings in shares of MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in shares of MindWalk in the fourth quarter valued at approximately $91,000. Jane Street Group LLC increased its stake in shares of MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after buying an additional 96,018 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after buying an additional 18,600 shares during the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

MindWalk Price Performance

Shares of NASDAQ:HYFT opened at $1.33 on Friday. The company has a 50 day moving average price of $1.56. The company has a market capitalization of $62.36 million, a PE ratio of -6.07 and a beta of 0.83. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72. MindWalk has a 1 year low of $0.99 and a 1 year high of $3.25.

MindWalk (NASDAQ:HYFT) last released its earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. As a group, analysts anticipate that MindWalk will post -0.21 EPS for the current fiscal year.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.